Draft Genetic Test Review
“This information is distributed solely for the purpose of pre dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by the Centers for Disease Control and Prevention. It does not represent and should not be construed to represent any agency determination or policy.”
Cystic Fibrosis
Glossary
(181KB)
Master List of References
Glossary of Genetic Terms Used in This Review
List of Reviewers
Listing of Reviewers' Comments and Specific Responses
MASTER LIST OF REFERENCES 96, 1997, 1998, 1999, 2000) College of American Pathologists, Northfield, IL.
American College of Obstetricians and Gynecologists. The best possible defense position. ACOG Department of Professional Liability, May 1985
Armstrong DS, Grimwood K, Carzino R, Carlin J, Olinsky A, Phelan PD. 1995. Lower respiratory tract infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 310:1570-1572.
Asch DA, Hershey JC, Dekay ML, Pauly MV, Patton JP, Jedrziewski MK, Frei F, Giardine R, Kant JA, Mennuti MT. 1998, Carrier screening for cystic fibrosis: costs and clinical outcomes. Med Decis Making 18:202-212.
Beech R, Bekker. 1996. Planning the development of cystic fibrosis gene carrier screening. J Health Serv Res Policy 1:81-92.
Bovicelli L, Rizzo N, Montacuti V, Morandi R. 1986. Transabdominal vs transcervical routes for chorionic villus . Lancet ii:290.
Bradley L, Johnson D, Chaparro C, Robertson N, Ferrie R. 1997. A multiplex ARMS test for 10 cystic fibrosis (CF) mutations: Evaluation in a prenatal CF screening program. Genet Test 2:337-341.
Bradley LA, Johnson DD, Doherty RA, Palomaki GE, Haddow JE. 1998. Routine prenatal cystic fibrosis screening in primary care offices. Am J Hum Genet 63:A13.
Bradley LA, Johnson DD, Palomaki GE, Haddow JE, Robertson NH, Ferrie RM. 1998 J Med Screen 5:34-36.
Brambati B, Terzian E, Tognoni G. 1992. Randomized clinical trial of transabdominal vs transcervical chorionic villus sampling methods. Prenat Diagn 11:285-293.
Brambati B, Anelli MC, Tului L. 1996. Prenatal cystic fibrosis screening in a low-risk population undergoing chorionic villus sampling for fetal karyotyping. Clin Genet 50:23-27.Brock DJH. 1996. Prenatal screening for cystic fibrosis: 5 years' experience reviewed. Lancet 347:148-150.
Brock DJH. 2000. Cystic fibrosis. In: Antenatal and Neonatal Screening. Second Edition. Wald N & Leck I (eds.). Oxford University Press: London, pp. 325-349.
Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hornbridge KM, et al. 1992. Pancreatic insufficiency, growth and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 120:533-540.
Cho MK, Arruda M, Holtzman NA. 1997. Educational material about genetic tests: Does it provide key information for patients and practitioners? Am J Med Genet 73:314-320.
Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell PW, Phillips JA. 1995. Teaching about cystic fibrosis carrier screening by using written and video information. Am J Hum Genet 57:171-281.
Couper RTL, Corey M, Moore DJ, Fisher J, Forstner GG, Durie PR. 1992. Decline of exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. Pediatr Res 32:170-182.
Coutts JAP, Docherty JG, Carachi R, Evans TJ. 1997. Clinical course of patients with cystic fibrosis presenting with meconium ileus. Br J Surg 84:555.
Cuckle HS, Richardson GA, Sheldon TA, Quirke P. 1994. Cost effectiveness of antenatal screening for cystic fibrosis. BMJ 311:1460-1464.
Cuckle H, Quirke P, Sehmi I, Lewis F, Murray J, Cross D, Cuckle P, Ozols B. 1996. Antenatal screening for cystic fibrosis. Br J Obstet Gynaecol 103:795-799.
Cunningham JC, Taussig LM. 1999. In: An Introduction to Cystic Fibrosis for Patients and Families. Cystic Fibrosis Foundation, p. 99.
Cuppens H, Cassiman JJ. 1995. A quality control study of CFTR mutation screening in 40 different European laboratories. The European Concerted Action on Cystic Fibrosis. Eur J Hum Genet 3:235-245.
Doak C, Doak L, Root J. 1995. Teaching patients with low literacy skills. JB Lippincott.
Dequeker E, Cassiman J. 2000. Genetic proficiency testing in diagnostic laboratories – quality control is the message. Am J Hum Genet 67:A274.
Dequeker E, Cassiman JJ. 2000. Genetic testing and quality control in diagnostic laboratories. Nat Genet 25:259-260.
Dequeker E, Cuppens H, Dodge J, Estivill X, Goossens M, Pignatti PR, Scheffer H, Schwartz M, Schwarz M, Tummler B, Cassiman JJ. 2000. Recommendations for the quality improvement of genetic testing in cystic fibrosis. European Concerted Action on Cystic Fibrosis. Eur J Hum Genet 8 (suppl. 2): S2-24.
Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Dostal DA, Haddow JE. 1994. Prenatal screening for cystic fibrosis. Lancet 343:172.
Doherty RA, Palomaki GE, Kloza EM, Erickson JL, Haddow JE. 1996. Couple-based prenatal screening for cystic fibrosis in primary care settings. Prenat Diagn 16:397-404.
Donaldson C, Shackley P, Abdalla M, Miedzybrodzka Z. 1995. Willingness to pay for antenatal screening for cystic fibrosis. Health Econ 4:439-452.
Donaldson C, Shackley P, Abdalla M. 1997. Using willingness to pay to value close substitutes: carrier screening for cystic fibrosis revisited. Health Econ 6:145-159.
Elles R. 1997. An overview of clinical molecular genetics. Mol Biotechnol 8:95-104.
Eng CM, Schechter C, Robinowitz J, Fulop G, Burgert T, Levy B, Zinberg R, Desnick RJ. 1997. Prenatal genetic carrier testing using triple disease screening. JAMA 278:1268-1272.
Fog Index can be computed at http://www.fpd.finop.umn.edu/groups/ppd/documents/information/writing_tips.cfm
Firth HV, Boyd PA, Chamberlain P, MacKenzie IZ, Lindenbaum RH, Huson SM. 1991. Severe limb abnormalities after chorion villus sampling at 56-66 days gestation. Lancet 337:762-763.
Fry E. Fry's readability graph: clarifications, validity, and extensions to level 17. J Read 1977:242-252.
Gaskin KJ, Gurwitz D, Durie P, Corey M, Levison H, Forstner G. 1982. Improved respiratory prognosis in patients with cystic fibrosis and normal fat absorption. J Pediatr 100:857-862.
Gasparini P, Arbustini E, Restagno, Zelante I, Stanziale P, Gatta L, Sbaiz L, Sedita AM, Banchieri N, Sapone L, Fiorucci GC, Brinson E, Shulse E, Rappaport E, Fortina P. 1999. Analysis of 31 CFTR mutations by polymerase chain reaction/oligonucleotide ligation assay in a pilot screening of 4476 newborns for cystic fibrosis. J Med Screen 6:67-69.
Genetic testing under the clinical laboratory improvement amendments. 2000. Federal Register;65:24928-24934
Ginsberg G, Blau H, Kerem E, et al. 1994. Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population. Health Economics 3:5-23.
Gosden C, Tabor A, Leck I, Grant A, Alfirevic Z, Wald N. (2000). Amniocentesis and chorionic villus sampling. In: Antenatal & Neonatal Screening. 2nd Edition. Wald & Leck (eds), Oxford University Press, pp. 470-516.
Grant AM. 1992. Transabdominal versus transcervical chorion villus sampling. In: Oxford Database of Perinatal Trials, version 1.2, Disk issue 7, (ed. I Chalmers), record no 6005.
Grody WW, Dunkel-Schetter C, Tatsugawa ZH, Fox MA, Fang CY, Cantor RM, Novak JM, Bass HN, Crandall BF. 1997. PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. Am J Hum Genet 60:935-947.
Grody W, Desnick R, Carpenter N, Noll W. 1998. Diversity of cystic fibrosis mutation-screening practices. Am J Hum Genet 62:1252-1254.
Grody W, Pyeritz R. 1999. Report card on molecular genetic testing: room for improvement? JAMA 281:845-847.
Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. 2001. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 3:149-54.
Grody WW, Desnick RJ. 2002. Cystic fibrosis population carrier screening: here at last – are we ready? Genet Med 3:88-91.
Grubman SA, Fang SL, Mulberg AE, Perrone RD, Rogers LC, Lee DW, et al. 1995. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 108:584-592.
Gutman S. 1999. The role of Food and Drug Administration regulation of in vitro diagnostic devices-Applications to genetic testing. Clin Chem 45:746-749.
Haddow JE, Bradley LA, Palomaki GE, Doherty RA, Bernhardt BA, Brock DJH, et al. 1999a. Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. Genet Med 1:129-135.
Haddow JE, Bradley LA, Palomaki GE, Doherty RA, Bernhardt BA, Brock DJH, et al. 1999b. Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference. J Med Screen 6:60-66.
Haddow JE, Palomaki GE, Bradley LA, Doherty RA. 1998. Screening for cystic fibrosis. JAMA 279:1068.
Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R. 1993. Cystic fibrosis carrier testing in early pregnancy by general practitioners. BMJ 306:1580-1583.
Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R. 1996. Pilot study of the acceptability of cystic fibrosis carrier testing during routine antenatal consultations in general practice. Br J Gen Pract 46:225-227.
Hartley NE, Scotcher D, Harris H, Williamson P, Wallace A, Craufurd D, Harris R. 1997. The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 34:459-464.
Hillyard S. 2001. Cystic fibrosis. Genetically programmed to self-destruct. Lancet 358:Suppl:S20.
Hofgartner W, Tait J. 1999. Frequency of problems during clinical molecular-genetic testing. Am J Clin Pathol 112:14-21.
Hofgartner W, Tait J. 1999. Characteristics of clinical molecular-genetic testing laboratories in the United States. Clin Chem 45:1288-1290.
Holloway S, Brock DJH. 1994. Cascade testing for the identification of carriers of cystic fibrosis. J Med Screen 1:159-164.
Holmes LB, Pyeritz RE (for the Clinical Practice Committee of the American College of Medical Genetics). 1998. Screening for cystic fibrosis. JAMA 279:1068-1069.
Holtzman NA, Watson MS. 1997. Promoting Safe and Effective Genetic Testing in the United States. Final report of the Task Force on Genetic Testing. http://biotech.law.lsu.edu/research/fed/tfgt/ , pp. 1-72.
Jung U, Urner U, Grade K, Coutelle C. 1994. Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population. Hum Genet 94:19-24.
Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui LC. 1989. Identification of the cystic fibrosis gene: genetic analysis. Science 245:1073-1080.
Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DWH. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:1075-1082.
Lanng S, Thorsteinsson B, Lund-Andersen C, Nerup J, Schiøtz, Koch C. 1994. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatr 83:72-77.
Leist JC, Kristoco RE. 1990. The changing paradigm for continuing medical education: impact of information on the teachable moment. Bull Med Libr Assoc 78:173-179.
Lieu TA, Watson SE, Washington AE. 1994. The cost-effectiveness of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 84:903-912.
Lippman A, Tomkins DJ, Shine J, Hamilton JL. 1992. Canadian multicentre randomised clinical trial of chorionic villus sampling and amniocentesis: final report. Prenat Diagn 12:385-476.
Littlewood JM. 1992. Gastrointestinal complications in cystic fibrosis. J R Soc Med 85 (suppl 18):13-19.
Livingstone J, Axton RA, Gilfillan A, Mennie M, Compton M, Liston WA, Calder AA, Gordon AJ, Brock DJH. 1994. Antenatal screening for cystic fibrosis: a trial of the couple model. BMJ 308:1459-1462.
Loader S, Caldwell P, Kozyra A, Levenkron JC, Boehm CD, Kazazian HH Jr., Rowley PT. 1996. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 59:234-247.
Loc, H, Adair S, Mathison, Abedor AJ, Griffin S. Practical Evaluation of Public Health Programs. Public Health Training Network, Centers for Disease Control, Atlanta, Georgia http://www.phppo.cdc.gov/phtn/Pract-Eval/workbook.asp
Loeben GL, Marteau TM, Wilfond BS. 1998. Mixed Messages: Presentation of information in cystic fibrosis-screening pamphlets. Am J Hum Genet 63:1181-1189.
Malfoot A, Dab I. 1991. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow-up. Arch Dis Child. 66:1339-1345.
Marteau T, Dundas R, Axworthy D. 1997. Long-term cognitive and emotional impact of genetic testing for carriers of cystic fibrosis: the effects of test result and gender. Health Psych 16:51-62.
Maurage C, Lenaerts C, Weber AM, Brochu P, Yousef I, Roy CC. 1989. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 9:17-20.
McGovern M, Benach M, Wallenstein S, Desnick R, Keenlyside R. 1999. Quality assurance in molecular genetic testing laboratories. JAMA 281:835-840.
Mennie ME, Gilfillan A, Compton M, Curtis L, Liston WA, Pullen I, Whyte DA, Brock DJ. 1992. Prenatal screening for cystic fibrosis. Lancet 340:214-216.
Mennie ME, Liston WA, Brock DJH. 1992. Prenatal cystic fibrosis carrier testing: designing an information leaflet to meet the specific needs of the target population. J Med Genet 29:308-312.
Mennuti M, Thomson E, Press N. 1999. Screening for cystic fibrosis carrier state. Obstet Gynecol 93:456-461.
Meyers MF, Bernhardt BA, Tambor ES, Holtzman NA. 1994. Involving consumers in the development of an educational program for cystic fibrosis carrier screening. Am J Hum Genet 54:719-726.
Miedzybrodzka ZH, Hall MH, Mollison J, Templeton A, Russell IT, Dean JCS, Kelly KF, Marteau TM, Haites NE. 1995. Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ 310:353-357.
Morris JK, Oppenheimer PM. 1995. Cost comparison of different methods of screening for cystic fibrosis. J Med Screen 2:22-27.
Murphy JL, Wooton SA, Bond SA, Jackson AA. 1991. Energy content of stools in healthy normal controls and patients with cystic fibrosis. Arch Dis Child 66:495-500.
Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J. 1999. Screening for cystic fibrosis. Health Technol Assess 3:1-104.
Murray J, Cuckle H. 2001. Cystic fibrosis and fragile X syndrome: the arguments for antenatal screening. Comb Chem High Throughput Screen 4:265-272.
NCCLS. Molecular diagnostic methods for genetic diseases; approved guideline. MM1-A Vol.20 No.7, 2000.
Neglia JP, FitzSimmons SC, Maisonneuve P, Schöni MH, Schöni-Affloter F, Corey M, et al. 1995. The risk of cancer among patients with cystic-fibrosis. N Engl J Med 332:494-499.
New York State Department of Health, Clinical Laboratory Evaluation Program, Laboratory Standards Rev 9/00 ( http://www.wadsworth.org/labcert/clep/Survey/standardsmenu.htm ).
Neumaier M, Braun A, Wagener N. 1998. Fundamentals of quality assessment of molecular amplification methods in clinical diagnosis. International Federation of Clinical Chemistry Scientific Division Committee on Molecular Biology Techniques. Clin Chem 44:12-26.
NIH Consensus Development Conference Statement. Genetic testing for cystic fibrosis. Available at
http://consensus.nih.gov/1997/1997GeneticTestCysticFibrosis106html.htm. Accessed June 3, 1997.
Notice of Intent; Genetic testing under the clinical laboratory improvement amendments. 2000 Federal Register 65:24928-34.
Ornoy A, Arnon J, Katznelson D, Granat M, Caspi B, Chemke A. 1987. Pathological confirmation of cystic fibrosis in the fetus following prenatal diagnosis. Am J Med Genet 28:935-947.
Padoan R, Marzano MT, Colombo C, Genoni S, Corbetta C, Seia M, et al. 1997. Genotype prognosis and clinical follow-up of cystic fibrosis patients with meconium ileus or neonatal intestinal obstruction [abstract]. Proceedings 21st European Cystic Fibrosis Conference (EWGCF), 157.
Palomaki GE, Knight GJ, McCarthy JE, Haddow JE, Donhowe JM. 1997. Maternal serum screening for Down syndrome in the United States: A 1995 survey. Am J Obstet Gynecol 16:1046-1051.
Petrou S, Henderson J, Roberts T, Martin MA. 2000. Recent economic evaluations of antenatal screening: a systematic review and critique. J Med Screen 7:59-73.
Rescorla FJ, Grosfield JL, West KJ, Vane DW. 1989. Changing pattern of treatment and survival of neonates with meconium ileus. Arch Surg 51:34-48.
Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. 1989. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066-1073.
Robinson R. 1999. Are we failing in molecular genetic testing? Am J Clin Pathol 112:11-13.
Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy K, Hidaka N, et al. 1989. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 245:1059-1065.
Rowley P, Loader S, Levenkron J. 1997. Issues in genetic testing. Cystic fibrosis carrier population screening: A review. Genet Test 1:53-59.
Rowley PT, Loader S, Kaplan RM. 1998. Prenatal screening for cystic fibrosis: An economic evaluation. Am J Hum Genet 63:1160-1174.
Schöni MH, Mainsonneuve P, Schöni-Affloter F, Lowenfels AB. 1996. Cancer risk in patients with cystic fibrosis: The European data. J R Soc Med 89 (suppl 27):38-43.
Schwartz M, Brandt NJ, Skovby F. 1993. Screening for carriers of cystic fibrosis among pregnant women: A pilot study. Eur J Hum Genet 1:239-244.
Schwarz MJ, Malone GM, Haworth A, Cheadle JP, Meredith AL, Gardner A, Sawyer IH, Connarty M, Dennis N, Seller A, et al. 1995. Cystic fibrosis mutation analysis: report from 22 UK regional genetics laboratories. Hum Mutat 6:326-333.
Schwartz M. 1999. Genetic testing and the clinical laboratory improvement amendments of 1988: present and future. Clin Chem 45:739-745.
Scott-Jupp R, Lama M, Tanner MS. 1991. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 66:698-701.
Secretary's Advisory Committee on Genetic Testing. Enhancing the oversight of genetic tests: Recommendations of the SACGT. (http://www4.od.nih.gov/oba/sacgt.htm).
Secretary's Advisory Committee on Genetic Testing. Federal Register 65:77631-77633.
Smidt-Jensen S, Permin M, Philip J, Lundsteen C et al. Randomized comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling Lancet, 340: 1237-44.
Stenhouse S, Middleton-Price H. Quality assurance in molecular diagnosis. The UK experience. (pp. 341-352). In: Methods in Molecular Medicine: Molecular diagnosis of genetic diseases. Edited by: R. Elles. Humana Press Inc., Totowa, NY.
Super M, Schwartz MJ, Malone G, Roberts T, Haworth A, Dermody G. 1994. Active cascade screening for carriers of cystic fibrosis gene. BMJ 308:1462-1468.
Tanner MS. 1992. Liver and biliary problems in cystic fibrosis. J R Soc Med 85 (suppl 19):20-24.
Tabor A, Philip J, Madsen M, Bang J, Obel E, Norgaard-Pedersen B. 1986. Randomised controlled trial of genetic amniocentesis in 4606 low risk women. Lancet i:1287-1293.
Tekfi, Chafai (1987) Readability Formulas: An Overview, J Docum 43:261-73.
The Cystic Fibrosis Genetic Analysis Consortium. 1990. Worldwide survey of the deltaF508 mutation. Am J Hum Genet 47:354-359.
US Congress, Office of Technology Assessment, Cystic Fibrosis and DNA Tests: Implications of carrier screening. OTA-BA-532 (Washington, DC: US Government Printing Office, August 1992).
Vintzileos AM, Ananth CV, Smulian JC, Fisher AJ, Day-Salvatore D, Beazoglou T. 1998. A cost-effectiveness analysis of prenatal carrier screening for cystic fibrosis. Obstet Gynecol 91:529-534.
Wald NJ, George LM, Wald NM, Mackenzie IZ. 1993. Couple screening for cystic fibrosis. Lancet 342:1307-1308.
Wald NJ, George L, Wald N, MacKenzie IZ. 1995. Further observations in connection with couple screening for cystic fibrosis. Prenat Diagn 15:589-590.
Wald NJ. 1999. Biochemical detection of neural tube defects and Down's syndrome. In: Turnbull's Obstetrics, 2nd Edition, G. Chamberlain (ed). Churchill Livingstone, Edinburgh, pp. 195-209.
Ward H, Rodeck C. 1993. Comparison of amniocentesis and transabdominal and transcervical chorionic villus sampling. Lancet 341:186-187.
Waters DL, Dorney SFA, Gaskin KJ, Grauca MA, O'Halloran M, Wilken B. 1990. Pancreatic function in infants identified as cystic fibrosis in a neonatal screening program. N Engl J Med 322:303-308.
Watson M. 1995. Current activities involving economic, regulatory, and practice issues in molecular genetic testing. Diagn Mol Pathol 4:233-234.
Wildhagen MF, Hilderink HB, Verzijl JG, Verheij JB, Kooij L, Tijmstra T, ten Kate LP, Habbema JD. 1998. Costs, effects, and savings of screening for cystic fibrosis gene carriers. J Epidemiol Community Health 52:459-467.
Wilfond BS, Fost N. 1992. The introduction of cystic fibrosis carrier screening into clinical practical: Policy considerations. Milbank Quarterly 70:629-659.
Witt DR, Schaefer C, Hallam P, Wi S, Blumberg B, Fishbach A, Holtzman J, Kornfeld S, Lee R, Nemzer L, Palmer R. 1996. Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet 58:823-835.
Woods P, Jeffrey B. Teachable moments. Open University Press, 1996.
|